Zansecimab

赞塞西单抗

Report date: 2025/05/24 20:00:06

Base Information

Drug NameZansecimab
Drug Alias NameLY-3127804
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAngiopoietin-2 inhibitors
TargetsAngiopoietin-2
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Solid tumoursPneumonia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesFrance +[4] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEli Lilly And Company
Active IndicationsN/A
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Solid tumoursPneumonia

Other Information

ATC CodeN/A
Related LinksN/A